No photo of Marshall Mazepa
Contact Expert

View Scopus Profile

Marshall Mazepa

20012020
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

  • 3 Similar Profiles
Thrombotic Thrombocytopenic Purpura Medicine & Life Sciences
Idiopathic Thrombocytopenic Purpura Medicine & Life Sciences
Blood Platelets Medicine & Life Sciences
Hemophilia A Medicine & Life Sciences
Plasma Exchange Medicine & Life Sciences
Hemorrhage Medicine & Life Sciences
Recurrence Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2017 2020

C-935788-053: A Phase 2, Multi-Center, Open Label, Simon

Mazepa, M.

RIGEL PHARMACEUTICALS, INC.

10/1/17 → 12/31/20

Project: Research project

Autoimmune Hemolytic Anemia
Safety
Antibodies
fostamatinib

Protocol ML39356: AN OPEN-LABEL, MULTICENTER, EXPANDED A

Mazepa, M.

Genentech Inc.

3/1/17 → 12/31/20

Project: Research project

Hemophilia A
OPEN protocol
emicizumab

Research Output 2001 2019

2 Citations (Scopus)

Endothelial alterations in a canine model of immune thrombocytopenia

LeVine, D. N., Cianciolo, R. E., Linder, K. E., Bizikova, P., Birkenheuer, A. J., Brooks, M. B., Salous, A. K., Nordone, S. K., Bellinger, D. A., Marr, H., Jones, S. L., Fischer, T. H., Deng, Y., Mazepa, M. & Key, N. S., Jan 2 2019, In : Platelets. 30, 1, p. 88-97 10 p.

Research output: Contribution to journal › Article

Open Access
Idiopathic Thrombocytopenic Purpura
von Willebrand Factor
Canidae
Thrombocytopenia
Blood Platelets

How targeted therapy disrupts the treatment paradigm for acquired TTP: The risks, benefits, and unknowns

Mazepa, M., Masias, C. & Chaturvedi, S., Aug 1 2019, In : Blood. 134, 5, p. 415-420 6 p.

Research output: Contribution to journal › Article

Thrombotic Thrombocytopenic Purpura
Platelets
Platelet Count
Refractory materials
Anti-Idiotypic Antibodies

Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies

Mazepa, M. A., Park, Y. A. & Raval, J. S., Jan 1 2019, (Accepted/In press) In : Transfusion Medicine Reviews.

Research output: Contribution to journal › Review article

Empiricism
Thrombotic Thrombocytopenic Purpura
Idiopathic Thrombocytopenic Purpura
von Willebrand Factor
Adrenal Cortex Hormones

The top 10 things to know about transfusion medicine before intern year: An evidence-based course for graduating medical students

Peedin, A. R., Perjar, I., Mazepa, M., Rollins-Raval, M. A., Park, Y. A. & Raval, J. S., Jun 1 2019, In : Blood Research. 54, 2, p. 125-130 6 p.

Research output: Contribution to journal › Article

Open Access
Transfusion Medicine
Medical Students
Students
Medical Schools
Color
2 Citations (Scopus)

Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura

Beckman, J. D., Rollins-Raval, M. A., Raval, J. S., Park, Y. A., Mazepa, M. & Ma, A., Mar 1 2018, In : American journal of therapeutics. 25, 2, p. e270-e272

Research output: Contribution to journal › Article

Open Access
Purpura
Idiopathic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Purpura
Proteasome Inhibitors
Proteasome Endopeptidase Complex